

Antibodies to SARS-CoV-2 are associated with protection against reinfection: Supplementary Material

Supplementary Methods

PCR platforms

RT-PCR was performed using the Public Health England SARS-CoV-2 assay (targeting the RdRp gene), one of five commercial assays: Abbott RealTime (targeting RdRp and N genes; Abbott, Maidenhead, UK), Altona RealStar (targeting E and S genes; Altona Diagnostics, Liverpool, UK), Cepheid Xpert® Xpress SARS-CoV-2 (targeting N2 and E; Cepheid, California, USA), BioFire® Respiratory 2.1 (RP2.1) panel with SARS-CoV-2 (targeting ORF1ab and ORF8; Biofire diagnostics, Utah, USA), Thermo Fisher TaqPath assay (targeting S and N genes, and ORF1ab; Thermo Fisher, Abingdon, UK) or using the ABI 7500 platform (Thermo Fisher, Abingdon, UK) with the US Centers for Disease Control and Prevention Diagnostic Panel of two probes targeting the N gene.


Software

All analyses were performed using R, version 3.6.3. Natural cubic splines were fitted with the splines library, using the default spline locations.

Sensitivity analysis


Rates of asymptomatic testing varied by antibody status, with seronegative healthcare workers (HCWs) attending more frequently than seropositive HCWs. To assess the impact on our results we performed a sensitivity analysis where we randomly removed PCR tests from the dataset. PCR tests were removed at random, irrespective of the result, from individuals with negative baseline serology until the overall rate of testing per 10,000 days at risk was equivalent in the seropositive and seronegative HCW groups. We used the resulting dataset to repeat our analysis.

Supplementary Figures




* NB HCWs who seroconvert during follow up were allowed to contribute to the analysis twice, once while at risk of infection and IgG negative and then subsequently while IgG positive.


Supplementary Figure S1. Flow diagram demonstrating cohort numbers from enrollment to final categorization into seropositive and seronegative groups. Panel A shows the cohort used in the primary analysis, using anti-spike IgG results only. Panel B shows the cohort used in the first secondary analysis using anti-nucleocapsid IgG results only. Panel C shows the cohort used in the second secondary analysis, using both anti-spike and anti-nucleocapsid IgG results.



Supplementary Figure S2. Non-linear relationship between age and incidence of PCR-positive results in HCWs with anti-spike antibody measurements. Estimates shown are adjusted for gender, month, and baseline antibody status.



Supplementary Figure S3. Non-linear relationship between age and incidence of PCR-positive results in HCWs with anti-nucleocapsid antibody measurements. Estimates shown are adjusted for gender, month, and baseline antibody status.



Supplementary Figure S4. Non-linear relationship between age and incidence of PCR-positive results in HCWs with both anti-spike and anti-nucleocapsid antibodies. Estimates shown are adjusted for gender, month, and baseline antibody status.

Supplementary Tables

		Whole cohort (n=12453)	First secondary analysis (anti-nucleocapsid IgG only)	
			Anti-nucleocapsid seronegative (n=11336)	Anti-nucleocapsid seropositive (includes 1117 initially seropositive HCWs and 45 who seroconverted)* (n=1162)
Age (years) Median (IQR), [Range]		38 (29-49) [16-86]	38 (28-49) [16-86]	39 (29-49) [17-70]
Gender n (%)	Female	9187 (73.8%)	8399 (74.1%)	822 (70.7%)
	Male	3246 (26.1%)	2919 (25.7%)	338 (29.1%)
	Other**	20 (0.2%)	18 (0.2%)	2 (0.2%)
Ethnicity n (%)	White	8992 (72.2%)	8336 (73.5%)	685 (59)
	Asian	2019 (16.2%)	1737 (15.3%)	290 (25%)
	Black	505 (4.1%)	427 (3.8%)	78 (6.7%)
	Chinese	130 (1.0%)	121 (1.1%)	9 (0.8%)
	Other	807 (6.5%)	715 (6.3%)	100 (8.6%)
Role n (%)	Nurse/HCA	4471 (35.9%)	3929 (34.7%)	562 48.4%
	Doctor	1847 (14.8%)	1674 (14.8%)	175 15.1%
	Administrative staff	1527 (12.3%)	1445 (12.7%)	89 7.7%
	Medical or nursing student	632 (5.1%)	606 (5.3%)	30 2.6%
	Laboratory staff	443 (3.6%)	409 (3.6%)	35 3%
	Physio/OT/Speech therapist	385 (3.1%)	346 (3.1%)	41 3.5%
	Porter/Domestic	376 (3%)	317 (2.8%)	59 5.1%
	Security/Estates/Catering	268 (2.2%)	242 (2.1%)	30 2.6%
	Other allied health professionals	2504 (20.1%)	2368 (20.9%)	141 12.1%
PCR- positive during follow up (n)	Total	172	169	3
	Symptomatic	89	88	1
	Asymptomatic	83	81	2

Supplementary Table S1. Baseline cohort demographics for 12453 healthcare workers included in the secondary analysis using anti-nucleocapsid IgG alone.

*Those who started anti-nucleocapsid antibody negative and then seroconverted (n=45) were allowed to contribute to the analysis twice, once while at risk of infection and antibody negative and then subsequently while antibody positive and at risk of re-infection.

**This category includes Trans and non-disclosed gender, amalgamated due to small numbers to prevent inadvertent identification.

	Unadjusted incidence rate ratio	Unadjusted 95% CI	Unadjusted P value	Adjusted incidence rate ratio	Adjusted 95% CI	Adjusted P value
Anti-spike IgG negative	1.00			1.00		
Anti-spike IgG positive	0.24	0.08, 0.76	0.015	0.26	0.08, 0.81	0.021
April-June	1.00			1.00		
July	0.17	0.08, 0.37	<0.001	0.18	0.08, 0.39	<0.001
August	0.18	0.09, 0.38	<0.001	0.19	0.09, 0.41	<0.001
September	0.27	0.15, 0.51	<0.001	0.29	0.16, 0.55	<0.001
October	0.78	0.52, 1.18	0.25	0.85	0.56, 1.28	0.44
November	1.78	1.22, 2.60	0.003	1.94	1.32, 2.83	0.001
Gender, Female	1.00			1.00		
Gender, Male	0.93	0.65, 1.31	0.66	0.94	0.66, 1.33	0.73
Age*						

Supplementary Table S2. Estimated regression parameters for the Poisson regression with anti-nucleocapsid antibody status as a binary variable adjusting for calendar month. 20 HCWs identifying as Trans or with a non-disclosed gender are not shown, as there were zero PCR-positive results in these individuals, 18 of whom were seronegative and 2 of whom were seropositive. *Age was fitted as a continuous variable with a 5 knot spline (Supplementary Figure S3).

		Whole cohort (n=12153)	Second secondary analysis (anti-spike +/- anti-nucleocapsid IgG)			
			Both assays negative (n=10866)	Anti-nucleocapsid positive only (n=135)	Anti-spike positive only (n=198)	Both assays positive* (n=1015)
Age Median (IQR), [Range]		38 (29-49) [16-86]	38 (29-49) [16-86]	35 (27-47) [20-70]	34 (26-44) [19-67]	40 (30-49) [17-69]
Gender n (%)	Female	8970 (73.8%)	8053 (74.1%)	101 (74.8%)	147 (74.2%)	713 (70.2%)
	Male	3163 (26.0%)	2796 (25.7%)	34 (25.2%)	50 (25.3%)	300 (29.6%)
	Other**	20 (0.2%)	17 (0.2%)	0 (0.0%)	1 (0.5%)	2 (0.2%)
Ethnicity n (%)	White	8792 (72.3%)	8012 (73.7%)	92 (68.1%)	141 (71.2%)	588 (57.9%)
	Asian	1963 (16.2%)	1656 (15.2%)	27 (20.0%)	32 (16.2%)	261 (25.7%)
	Black	490 (4.0%)	404 (3.7%)	6 (4.4%)	10 (5.1%)	71 (7.0%)
	Chinese	124 (1.0%)	114 (1.0%)	1 (0.7%)	2 (1.0%)	7 (0.7%)
	Other	784 (6.5%)	680 (6.3%)	9 (6.7%)	13 (6.6%)	88 (8.7%)
Role n (%)	Nurse/HCA	4390 (36.1%)	3788 (34.9%)	58 (43.0%)	71 (35.9%)	499 (49.2%)
	Doctor	1797 (14.8%)	1593 (14.7%)	26 (19.3%)	35 (17.7%)	147 (14.5%)
	Administrative staff	1496 (12.3%)	1392 (12.8%)	10 (7.4%)	23 (11.6%)	79 (7.8%)
	Medical or nursing student	584 (4.8%)	545 (5.0%)	2 (1.5%)	16 (8.1%)	26 (2.6%)
	Laboratory staff	432 (3.6%)	392 (3.6%)	4 (3.0%)	7 (3.5%)	31 (3.1%)
	Physio/OT/Speech therapist	377 (3.1%)	331 (3.0%)	11 (8.1%)	8 (4.0%)	30 (3.0%)
	Porter/Domestic	367 (3.0%)	304 (2.8%)	7 (5.2%)	5 (2.5%)	51 (5.0%)
	Security/Estates/Catering	260 (2.1%)	234 (2.2%)	4 (3.0%)	1 (0.5%)	25 (2.5%)
	Other allied health professionals	2450 (20.2%)	2287 (21.0%)	13 (9.6%)	32 (16.2%)	127 (12.5%)
Positive PCR during follow up	Total		160	1	1	2
	Symptomatic		87	1	0	0
	Asymptomatic		73	0	1	2

Supplementary Table S3. Baseline cohort demographics for 12153 healthcare workers included in the secondary analysis using a combination of anti-nucleocapsid and anti-spike IgG. *Those who started antibody negative and then seroconverted were allowed to contribute to the analysis twice, once while at risk of infection and antibody negative and then subsequently while antibody positive and at risk of re-infection. **This category includes Trans and non-disclosed gender, amalgamated due to small numbers to prevent inadvertent identification.

	Unadjusted incidence rate ratio	Unadjusted 95% CI	Unadjusted P value	Adjusted incidence rate ratio	Adjusted 95% CI	Adjusted P value
Both IgG assays negative	1.00			1.00		
Both IgG assays positive	0.19	0.05, 0.78	0.021	0.20	0.05, 0.81	0.024
Only one IgG assay positive	0.65	0.16, 2.62	0.54	0.67	0.16, 2.71	0.57
April-June	1.00			1.00		
July	0.18	0.08, 0.39	<0.001	0.19	0.09, 0.42	<0.001
August	0.19	0.09, 0.40	<0.001	0.21	0.10, 0.44	<0.001
September	0.27	0.14, 0.51	<0.001	0.29	0.15, 0.55	<0.001
October	0.84	0.55, 1.27	0.40	0.91	0.60, 1.38	0.67
November	1.81	1.22, 2.67	0.003	1.98	1.33, 2.93	0.001
Gender, Female	1.00			1.00		
Gender, Male	0.99	0.69, 1.40	0.94	1.00	0.71, 1.43	0.99
Age*						

Supplementary Table S4. Estimated regression parameters for the Poisson regression with both anti-spike and anti-nucleocapsid IgG antibody status adjusting for calendar month. 20 HCWs identifying as Trans or with a non-disclosed gender are not shown, as there were zero PCR-positive results in these individuals, 17 of whom were seronegative on both tests and 2 of whom were seropositive on both tests and 1 who was seropositive on only one test. *Age was fitted as a continuous variable with a 5 knot spline (Supplementary Figure S4). Of 333 tests where only one assay was positive, 135 were positive for anti-nucleocapsid only and 198 for anti-spike only.

ID	Demographics	Baseline serology	Time between episodes*	Clinical characteristics	Timing of PCR, Ct value and assay
HCW 1	28F, White	Anti-spike: not detected (<1 million) Anti-nucleocapsid: detected (5.94)	160 days	1st episode: asymptomatic 2nd episode: symptomatic (mild, febrile illness)	1st episode: not done (prior to start of asymptomatic testing) 2nd episode: Cn 10.6 (Abbott, RdRp/N assay), not repeated
HCW 2	56F, White	Anti-spike: detected (10.4 million) Anti-nucleocapsid: detected (7.52)	190 days	1st episode: symptomatic (mild, covid-19-like symptoms) 2nd episode: asymptomatic	1st episode: Ct 36.0 (PHE RdRp assay) 2nd episode: Cn 21.2 (Abbott RdRp/N assay), repeat PCR on day 2 and day 4 both negative
HCW 3	52F, White	Anti-spike: detected (8.8 million) Anti-nucleocapsid: not detected (0.02)	199 days	1st episode: symptomatic (mild) 2nd episode: asymptomatic when tested (transient myalgia following influenza vaccine previous week)	1st episode: PCR-negative 2nd episode: Cn 12.6 (Abbott RdRp/N assay), repeat day 2 Ct 24.0 (Altona E/S gene)
HCW 4	26F, Asian	Anti-spike: detected (11.6 million) Anti-nucleocapsid: detected (3.9)	231 days	1st episode: symptomatic (mild, fever and anosmia) 2nd episode: asymptomatic	1st episode: not done (prior to start of symptomatic staff testing) 2nd episode: Ct 10 (Thermofisher, N gene assay), not repeated

Supplementary Table S5. Demographic, clinical and laboratory characteristics of individuals with possible SARS-CoV-2 reinfection. *Time between episodes is calculated from date of positive PCR if index infection was PCR-positive (HCW 2 and 3), date of symptom onset if index infection was symptomatic but no PCR was performed (HCW 4), or date of first clinic attendance if presumed first episode was asymptomatic with no PCR performed (HCW 1).